Also found in: Medical.
MUC1Mucine-1 (protein targeted in Cancerous cells)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
TG4010 is an active immunotherapy designed to express the coding sequences of the MUC1 tumor-associated antigen and the cytokine, Interleukin-2 (IL2).
Immunohistochemical comparison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact.
Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 and MUC16.
En resumen, presentamos un caso de NPIC en un paciente joven, cuyo diagnostico fue confirmado por anatomia patologica tras una colecistectomia electiva, descartandose la presencia de carcinoma invasivo y displasia de alto grado, por lo que el pronostico es favorable a pesar de presentar positividad para MUC1.
CV301 targets two tumour-associated antigens, CEA and MUC1, which are over-expressed in multiple solid tumours, including lung, bladder, colorectal and pancreatic cancers.
Based on the examinations assessing MUC1 expression, a significant increase in the expression of this glycoprotein was found as well as a relation was proved with invasiveness of cancerous cells, among others, in breast cancer, invasive pancreatic ductal adenocarcinoma, invasive cholangiocarcinoma, intraductal papillary mucinous neoplasm (IPMN) of the pancreas and adenocarcinoma of the bile ducts [6].
for co-developing cancer immunotherapies based on the MUC1 tumor-associated antigen.
Joshi et al., "Immunohistochemical study of MUC1, MUC2 and MUC5AC expression in primary breast carcinoma," Journal of Clinical and Diagnostic Research, vol.
Trivedi et al., "MUC1 oncoprotein activates the IkB kinase complex and constitutive NF-[kappa]B signalling," Nature Cell Biology, vol.
Their confirmatory experiments also showed that MUC1 mRNA is a target gene of miR-455-3p.
Pancreatic cancer exhibits a number of tumor-specific antigens, such as carcinoembryonic antigen, mesothelin, HER-2, and MUC1, which are promising applicants for testing CARs T-cell therapy [55,56].